- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech High Insider Buying
Hong Kong Pharmaceuticals & Biotech High Insider Buying
Results
21
Stocks with high levels of insider buying the past 3 months and good analyst coverage.
21 companies
CSPC Pharmaceutical Group
Market Cap: HK$107.6b
An investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally.
1093
HK$9.41
7D
6.9%
1Y
-9.3%
Akeso
Market Cap: HK$81.9b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$88.90
7D
-2.3%
1Y
-47.4%
3SBio
Market Cap: HK$44.0b
An investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally.
1530
HK$17.66
7D
3.9%
1Y
-41.3%
Sunshine Lake Pharma
Market Cap: HK$22.6b
Engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology.
6887
HK$39.22
7D
3.2%
1Y
-19.1%
Duality Biotherapeutics
Market Cap: HK$17.7b
A clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally.
9606
HK$195.70
7D
7.3%
1Y
-40.4%
Fujian Haixi Pharmaceuticals
Market Cap: HK$15.7b
Engages in research and development, production, and sale of pharmaceutical products in China.
2637
HK$200.00
7D
-7.8%
1Y
n/a
Nanjing Leads Biolabs
Market Cap: HK$14.8b
A clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs worldwide.
9887
HK$74.60
7D
2.2%
1Y
13.0%
Everest Medicines
Market Cap: HK$13.0b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$36.84
7D
25.8%
1Y
-50.2%
Suzhou Ribo Life Science
Market Cap: HK$10.3b
Researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chinese mainland and internationally.
6938
HK$60.50
7D
16.7%
1Y
n/a
CStone Pharmaceuticals
Market Cap: HK$9.3b
A biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.
2616
HK$5.84
7D
8.4%
1Y
-46.1%
Alphamab Oncology
Market Cap: HK$7.9b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People’s Republic of China.
9966
HK$8.13
7D
0.8%
1Y
-20.6%
Shanghai Haohai Biological Technology
Market Cap: HK$7.2b
Shanghai Haohai Biological Technology Co., Ltd.
6826
HK$16.49
7D
-0.5%
1Y
-42.8%
Jiangxi Institute of Biological Products
Market Cap: HK$5.6b
Jiangxi Institute of Biological Products Inc.
6915
HK$18.10
7D
33.1%
1Y
n/a
Shanghai Bao Pharmaceuticals
Market Cap: HK$5.2b
A biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China.
2659
HK$15.91
7D
-3.9%
1Y
n/a
Edding Genor Group Holdings
Market Cap: HK$3.0b
Engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally.
6998
HK$1.50
7D
-8.0%
1Y
-68.4%
Laekna
Market Cap: HK$2.6b
An investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide.
2105
HK$6.16
7D
-8.3%
1Y
-62.1%
Kintor Pharmaceutical
Market Cap: HK$871.6m
A clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology.
9939
HK$1.77
7D
3.8%
1Y
-23.6%
JW (Cayman) Therapeutics
Market Cap: HK$817.9m
A clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China.
2126
HK$2.02
7D
8.0%
1Y
-66.6%
3D Medicines
Market Cap: HK$750.1m
A biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products in the People’s Republic of China.
1244
HK$3.05
7D
64.0%
1Y
-61.6%
Lee's Pharmaceutical Holdings
Market Cap: HK$653.6m
An investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally.
950
HK$1.11
7D
-4.7%
1Y
-44.5%
Sirnaomics
Market Cap: HK$408.4m
An RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs in the People’s Republic of China.
2257
HK$3.75
7D
-8.4%
1Y
-62.5%